References
- Poire X, van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011;11(8):1099–1111.
- Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357–4363.
- Kline J, Pollyea D, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37(3):307–310.
- Green K, Pearce K, Sellar RS, et al. Impact of alemtuzumab scheduling on graft-versus-host disease after unrelated donor fludarabine and melphalan allografts. Biol Blood Marrow Transplant. 2017;23(5):805–812.
- Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010;116(16):3080–3088.
- Patel K, Parmar S, Shah S, et al. Comparison of subcutaneous versus intravenous alemtuzumab for graft-versus-host disease prophylaxis with fludarabine/melphalan-based conditioning in matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):456–461.
- Thoulouli E. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for AML and poor risk MDS. Br J Haematol. 2008;142:308–326.
- Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol. 2008;141(2):235–243.
- Choe HK, Gergis U, Mayer SA, et al. The addition of low-dose total body irradiation to fludarabine and melphalan conditioning in haplocord transplantation for high-risk hematological malignancies. Transplantation. 2017;101(1):e34–e8.
- Isa F, Saito K, Huang YT, et al. Implementation of molecular surveillance after a cluster of fatal toxoplasmosis at 2 neighboring transplant centers. Clin Infect Dis. 2016;63(4):565–568.
- Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
- Kullberg-Lindh C, Mellgren K, Friman V, et al. Opportunistic virus DNA levels after pediatric stem cell transplantation: serostatus matching, anti-thymocyte globulin, and total body irradiation are additive risk factors. Transpl Infect Dis. 2011;13(2):122–130.
- Park M, Lee YH, Lee SH, on behalf of the Cord Blood Transplantation Working Party of the Korean Society of Hematology, et al. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients. Ann Hematol. 2015;94(3):481–489.
- Deeg HJ, Stevens EA, Salit RB, et al. Transplant conditioning with treosulfan/fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2018;24(5):956–963.
- Kodiyanplakkal RP, Brown M, Guarneri D, et al. Efficacy of letermovir prophylaxis in cytomegalovirus seropositive allogeneic hematopoietic stem cell transplant recipients receiving in-vivo T-cell depletion. Bone Marrow Transplantation. 2019;54(Suppl. 1):419–420.